

Defining atherothrombotic risk in peripheral artery disease

Citation for published version (APA):

Kremers, B. (2023). *Defining atherothrombotic risk in peripheral artery disease*. [Doctoral Thesis, Maastricht University]. Maastricht University. <https://doi.org/10.26481/dis.20231124bk>

Document status and date:

Published: 01/01/2023

DOI:

[10.26481/dis.20231124bk](https://doi.org/10.26481/dis.20231124bk)

Document Version:

Publisher's PDF, also known as Version of record

Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

www.umlib.nl/taverne-license

Take down policy

If you believe that this document breaches copyright please contact us at:

repository@maastrichtuniversity.nl

providing details and we will investigate your claim.

IMPACT PARAGRAPH

Peripheral artery disease (PAD) is a common manifestation of atherosclerosis with a global prevalence of 5.6% and an even higher prevalence in high-income countries (7.4%). These numbers are estimates, as the disease remains underdiagnosed due to lack of awareness of clinical manifestations. Awareness was improved after the introduction of the ankle brachial index as diagnostic tool, but still millions of people with PAD are not being treated with the current medical treatment strategies as they have yet to be diagnosed with the disease. The patients that are diagnosed with PAD do not receive the current optimal treatment strategies. They are however still at increased risk for cardiovascular events, with cardiovascular mortality being increased three-fold in PAD patients as compared to non-PAD patients. People who are diagnosed with the disease also have, apart from the increased adverse event risk, two times higher odds of having impaired physical function, with PAD being consistently associated with a reduction of the physical component of quality of life. Moreover, PAD considerably increases medical expenditure, especially in PAD requiring major amputation where the expenditure is twelve times higher as compared to people without PAD.

To decrease the number of adverse events and medical expenditure, as well as to improve quality of life, it is important to understand why certain PAD patients are at increased risk for vascular complications and why the current medical treatment strategies are insufficient in preventing adverse events. This thesis revealed that the lipid-lowering strategy can be intensified to further improve lipid profiles. Moreover, antiplatelet agents appear to be inadequate in preventing adverse events with platelet reactivity being insufficiently decreased in patients who suffer from such events. Alternative medical strategies have been proposed, where the addition of a low dose of a direct anticoagulant drug to the standard antiplatelet therapy reduces the risk of cardiovascular events by 24%. This specific treatment strategy not only improves health outcomes, it also appeared to be cost-effective as compared to the standard antiplatelet therapy, especially in comorbid patients.

An important question however remains; who would benefit from such alternative treatment strategy? The combination of a low dose anticoagulant drug comes with a 70% increase in major bleeding events, and it is important not to expose patients to this increased bleeding risk when they are successfully treated with antiplatelet drugs only. Risk stratification could aid in creating tailored treatment strategies for PAD patients. In this thesis, biomarkers were identified, both newly found and as identified in the systematic review, that could be used for risk stratification. Along with these biomarkers, other variables such as prior ischemic events and decreased kidney function could be used in risk stratification models. Being able to stratify cardiovascular risk in PAD patients, medication strategies can be tailored and thereby the number of cardiovascular events can be reduced and quality of life can be preserved.